BMC cancer 2009, 9:125.PubMedCrossRef 24. Haferkamp A, Bedke J, Vetter C, Pritsch M, Wagener N, Buse S, Crnkovic-Mertens I, Hoppe-Seyler K, Macher-Goeppinger S, Hoppe-Seyler F, Autschbach F, Hohenfellner

M: High nuclear livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU international 2008, 102:1700–1706.PubMedCrossRef AZD8931 in vitro 25. Liu HB, Kong CZ, Zeng Y, Liu XK, Bi JB, Jiang YJ, Han S: Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urologic oncology 2009, 27:277–283.PubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions LQ proposed the study and wrote the first draft. WB analyzed the data. All authors contributed to the design and interpretation of the study and to further drafts. ZSS is the guarantor. All authors read and approved the final manuscript.”
“Background Lung cancer is the leading cause of cancer-related morbidity and mortality, resulting in more

than 1 million deaths per year worldwide[1]. In Brazil, the current estimatives of incidence are 18.37/100.000 and 9.82/100.000 for men and women, respectively[2]. find more About 70% of patients with lung cancer present locally advanced or metastatic disease at the time of diagnosis, because there is no efficient method to improve the early diagnosis[3] and this fact has a huge impact on treatment outcomes. In spite of the aggressive treatment with surgery, radiation, and chemotherapy, the long-term survival for patients with lung cancer still remains low. Even

patients with early stage disease often succumb to lung cancer due to the development of metastases, indicating the need for effective approaches for the systemic therapy of this condition [4]. A variety of novel approaches are now being investigated ROS1 to improve the click here outlook for management of this disease. Theories have also been postulated regarding the failure of the immune systems to prevent the growth of tumors. However, despite significant advances in our understanding of the molecular basis of immunology, many obstacles remain in translating this understanding into the clinical practice in the treatment of solid tumors such as lung cancer[1]. Dendritic cells (DCs) are the most potent antigen presenting cells with an ability to prime both a primary and secondary immune response to tumor cells. DCs in tumors might play a stimulating and protective role for effector T lymphocytes, and those DCs that infiltrate tumor tissue could prevent, by co-stimulating molecules and secreting cytokines, tumor-specific lymphocytes from tumor-induced cell death[5]. We believe that tumor vaccines may play an adjuvant role in NSCLC by consolidating the responses to conventional therapy.